Future perspectives in specific immunotherapy of melanoma

This publication has 23 references indexed in Scilit:

• Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
  The Journal of Experimental Medicine, 1996
• Analysis of Expression of the Melanoma-Associated Antigens MART-1 and gp lOO in Metastatic Melanoma Cell Lines and in In Situ Lesions
  Journal of Immunotherapy, 1996
• Human tumor antigens recognized by T lymphocytes.
  The Journal of Experimental Medicine, 1996
• Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy
  Immunology Today, 1996
• Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses
  Immunology Today, 1995
• Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3
  International Journal of Cancer, 1995
• Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevance
  Immunology Today, 1995
• Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells
  Immunology Today, 1993
• Treatment of Human Melanoma with a Hapten‐Modified Autologous Vaccinea
  Annals of the New York Academy of Sciences, 1993
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine
  Annals of Surgery, 1992